Last update 10 May 2025

SCT-C21

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
SCTC21, SCTC21C
Target
CD38
Action
inhibitors
Mechanism
CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors)
Therapeutic Areas
Immune System DiseasesUrogenital DiseasesNeoplasms+ [1]
Active Indication
Glomerulonephritis, IGACD38-Positive Hematologic NeoplasmsHematologic Neoplasms+ [1]
Inactive Indication-
Originator Organization
Sinocelltech Group Ltd.Sinocelltech Group Ltd.
Active Organization
Shenzhou Cell Engineering Co. Ltd.Shenzhou Cell Engineering Co. Ltd.Sinocelltech Group Ltd.Sinocelltech Group Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with SCT-C21
NCT06774664
/ Not yet recruitingPhase 1/2
A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTC21C in Subjects With Plasma Cell-driven Autoimmune Diseases
NCT06252298
/ RecruitingPhase 1
A Phase I Clinical Study Evaluating the Safety and Efficacy of SCTC21C in Participants With CD38+ Hematologic Malignancies
100 Clinical Results associated with SCT-C21
Login to view more data
100 Translational Medicine associated with SCT-C21
Login to view more data
100 Patents (Medical) associated with SCT-C21
Login to view more data
100 Deals associated with SCT-C21
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glomerulonephritis, IGAPhase 2
China
Sinocelltech Group Ltd.Sinocelltech Group Ltd.
01 Jan 2025
CD38-Positive Hematologic NeoplasmsPhase 1
China
Sinocelltech Group Ltd.Sinocelltech Group Ltd.
28 Feb 2024
Hematologic NeoplasmsIND Approval
China
Shenzhou Cell Engineering Co. Ltd.Shenzhou Cell Engineering Co. Ltd.
18 Jan 2024
Plasma Cell NeoplasmsIND Application
China
Shenzhou Cell Engineering Co. Ltd.Shenzhou Cell Engineering Co. Ltd.
14 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free